340B Health

340B Insight Podcast

340B Insight

340B Insight is 340B Health’s podcast, providing our members and supporters with timely news updates and discussion around the 340B drug pricing program. The podcast enables listeners to stay current and expand their knowledge of 340B to help them serve their patients and communities and remain compliant with rules and requirements. New episodes are published twice per month and include news update segments and in-depth interviews with leading experts including health care practitioners, policy and legal experts, public policymakers, and our expert staff.

Listen and Subscribe

Have a question or suggestion for 340B Insight? Email us at: podcast@340bhealth.org

Podcast sponsorship opportunities are available. Email to learn more: robin.hayes@340bhealth.org

Follow 340B Health on Twitter, Facebook, and LinkedIn

 


Episodes

  • Episode 109: What’s in the First State 340B Report in the Nation?

    A Minnesota requirement for covered entities to submit data on the costs they pay and the payments they receive for 340B drugs yielded its first annual report this past November. Today’s guest, Minnesota Hospital Association Director of State Government Relations Danny Ackert, tells us why the report’s findings don’t tell the whole story. (Transcript)

    Read more

  • Episode 108: The Fight Over Rebates Heats Up

    Earlier this year, the Health Resources & Services Administration took a strong stance against drug giant Johnson & Johnson’s plan for a proposed 340B rebate model, but the fight over rebates is far from over. 340B Health President and CEO Maureen Testoni joins us to discuss how the company is taking the issue to federal court and how they are not the only drugmaker doing so. (Transcript)

    Read more

  • Episode 107: What Does the GOP Trifecta Mean for 340B?

    In January, Republicans will achieve what’s known as a governing trifecta – taking control of the executive branch combined with GOP majorities in both the U.S. House and Senate. How will this new dynamic affect the 340B world? We discuss what is ahead with McDermott+ vice presidents Rodney Whitlock, a former Republican legislative staffer, and Debbie Curtis, a former Democratic legislative staffer. (Transcript)

    Read more

  • Episode 106: How 340B Funds an Innovative Program for Cancer Survivors

    The focus of attention on cancer care most often goes to the curative treatments required to put cancer into remission, but what do cancer survivors need after that point to fully recover and lead their best possible lives? We discuss that question and how 340B can help answer it with guests Sarah Loschiavo and Ellen Morris-White, two nurse practitioners with UConn Health based in Farmington, Conn. (Transcript)

    Read more

  • Episode 105: How 340B Is All About Health Equity

    The 340B drug pricing program is crucial for safety-net hospitals and other providers that care for patients in need, especially those whom traditionally have been underserved by the broader health system. We speak with Dr. Tony Jackson, assistant vice president for pharmacy services at Scripps Health in San Diego, for his views on why 340B is “all about health equity.” (Transcript)

    Read more

  • Episode 104: How Hospitals Won This Round in the 340B Rebate Fight

    Within the past few weeks, drugmaker Johnson & Johnson went head-to-head with 340B hospitals and the federal government over the company’s plan to stop paying upfront 340B discounts on two of its top-selling drugs. 340B Health Senior Counsel Amanda Nagrotsky joins us to explain how that conflict played out. (Transcript)

    Read more